Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 5/20 | 0.38 |
| ▸ | NMT2 | O60551 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15507749 | 1.00 | LMNA (0.43) | LMNAHPGDMEN1KMT2AHSP90AA1 | |
| SCHEMBL22716307 | 0.89 | FFAR1 (0.41) | LMNAMEN1KMT2AHSP90AA1FFAR1 | |
| SCHEMBL22716308 | 0.89 | FFAR1 (0.41) | LMNAMEN1KMT2AHSP90AA1FFAR1 | |
| SCHEMBL2309355 | 0.84 | MAP3K7 (0.51) | LMNAHPGDMEN1KMT2APABPC1 | |
| SCHEMBL2309352 | 0.84 | MAP3K7 (0.51) | LMNAHPGDMEN1KMT2APABPC1 | |
| SCHEMBL23555513 | 0.83 | L3MBTL1 (0.39) | HPGDMEN1KMT2APABPC1KDM4E | |
| SCHEMBL13424079 | 0.82 | LMNA (0.47) | LMNAHPGDMEN1KMT2AFFAR1 | |
| SCHEMBL2310751 | 0.77 | LMNA (0.49) | LMNAHPGDMEN1KMT2APABPC1 | |
| SCHEMBL4283870 | 0.77 | LMNA (0.49) | LMNAHPGDMEN1KMT2APABPC1 | |
| SCHEMBL23536718 | 0.76 | KDM4E (0.38) | LMNAHPGDKMT2AKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897877-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-02-13 | — | — | US | disclosed |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2022-12-22 | — | — | US | disclosed |
| US-11046688-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-29 | — | — | US | disclosed |
| US-20200165241-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2020-05-28 | — | — | US | disclosed |
| US-10479788-B2 | Compounds that inhibit MPS1 kinase | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-11-19 | — | — | US | disclosed |
| EP-3293183-B1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2019-07-24 | — | — | EP | disclosed |
| US-20180141944-A1 | INHIBITOR COMPOUNDS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-05-24 | — | — | US | disclosed |
| EP-3293183-A1 | INHIBITOR COMPOUNDS | Cancer Research Technology Ltd. (GB) | 2018-03-14 | — | — | EP | disclosed |
| US-9890157-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-13 | — | — | US | disclosed |
| US-9834552-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-12-05 | — | — | US | disclosed |
| EP-2892889-B1 | INHIBITOR COMPOUNDS | CANCER RES TECH LTD (GB) | 2017-10-18 | — | — | EP | disclosed |
| US-9409907-B2 | Inhibitor compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-09 | — | — | US | disclosed |
| US-20160222009-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160220570-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20150239884-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-27 | — | — | US | disclosed |
| EP-2892889-A1 | INHIBITOR COMPOUNDS | Cancer Research Technology Ltd (GB) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014037750-A1 | INHIBITOR COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479788-B2 | Compounds that inhibit MPS1 kinase | BUB1B, BUB1, CDK1 | LMNA 1312/4885HPGD 4473/4885MEN1 601/4885 |
| US-20220402912-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | LMNA 1306/4885HPGD 4376/4885MEN1 457/4885 |
| US-20150239884-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | LMNA 1306/4885HPGD 4376/4885MEN1 457/4885 |
| US-11046688-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | LMNA 1306/4885HPGD 4376/4885MEN1 457/4885 |
| US-20180141944-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | LMNA 1306/4885HPGD 4376/4885MEN1 457/4885 |
| US-20160222009-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | LMNA 1306/4885HPGD 4376/4885MEN1 457/4885 |
| US-11897877-B2 | Inhibitor compounds | BUB1B, BUB1, CDK1 | LMNA 1306/4885HPGD 4376/4885MEN1 457/4885 |
| US-20200165241-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | LMNA 1306/4885HPGD 4376/4885MEN1 457/4885 |
| US-20160220570-A1 | INHIBITOR COMPOUNDS | BUB1B, BUB1, CDK1 | LMNA 1306/4885HPGD 4376/4885MEN1 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.